Former Chief Operating Officer · INOVIO PHARMACEUTICALS, INC. (INO)

Niranjan Sardesai

A named executive officer of INOVIO PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,347,984

Salary $448,101Stock awards $354,783

FY2017: $1,480,618

2nd of 4 named executive officers at Inovio Pharmaceuticals by FY2018 total.

4 named officers on file for INOVIO PHARMACEUTICALS, FY2018

Niranjan Sardesai’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • INO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how INOVIO PHARMACEUTICALS’s whole pay program stands against its peers

  • INOVIO PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on INO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 25, 2019 (DEF 14A).

Free

Get Niranjan Sardesai’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Niranjan Sardesai compensation by year

INOVIO PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as INOVIO PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$409,715$435,051$448,101
Bonus$0$0$0
Stock awards$526,500$450,078$354,783
Option awards$290,838$437,586$358,612
Non-equity incentive$156,311$148,750$171,238
Pension and deferred compensation$0$0$0
All other$9,418$9,153$15,250
Total$1,392,782$1,480,618$1,347,984

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INOVIO PHARMACEUTICALS, INC. DEF 14A filed March 25, 2019, accession 0001055726-19-000021, and prior-year filings. Open the filing on EDGAR.

How this page was built: the INOVIO PHARMACEUTICALS, INC. filed document, accession 0001055726-19-000021. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2019.

$1.4M
$1.5M
$1.3M
FY16
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU82,700$330,800—
RSU40,866$163,464—
RSU25,000$100,000—
Option16,875—$7.02
Option50,000—$6.68
Option94,875—$4.29

Per the Outstanding Equity Awards at Fiscal Year-End table in INOVIO PHARMACEUTICALS, INC.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

INOVIO PHARMACEUTICALS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
J KimPresident, Chief Executive Officer and Director$3,081,043
Niranjan Sardesai · this pageFormer Chief Operating Officer$1,347,984
Mark BagarazziFormer Chief Medical Officer$1,345,888
Peter KiesChief Financial Officer$1,331,612

The full INOVIO PHARMACEUTICALS compensation record

free company brief

This page is one person within INOVIO PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the INOVIO PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INOVIO PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Niranjan Sardesai's compensation dossier · One-time report. No refunds.